Poor
Mostly Misaligned
Patient Risk:
Low
Summary
The provided label excerpts are for KESIMPTA (multiple sclerosis) and include contraindications/warnings/adverse reactions, but do not support any of the other ofatumumab patent/CLL/rheumatoid arthritis or mechanism claims. Only the MS indication claim is supported; the remainder are unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Section 1 INDICATIONS AND USAGE excerpt: "KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults."
Unsupported Statements
Ofatumumab (Arzerra) is a human monoclonal antibody that targets the CD20 protein found on the surface of B cells.
No mechanism-of-action/target description for ofatumumab (Arzerra) is present in the supplied label excerpts.
Ofatumumab promotes apoptosis of B cells.
No statement about apoptosis of B cells is present in the supplied label excerpts.
Ofatumumab is used for the treatment of chronic lymphocytic leukemia (CLL).
No CLL indication is present in the supplied label excerpts (which provide KESIMPTA MS indication only).
Ofatumumab is used for the treatment of rheumatoid arthritis.
No rheumatoid arthritis indication is present in the supplied label excerpts.
Ofatumumab is protected by several patents.
No patent/exclusivity information is included in the supplied label excerpts.
The earliest ofatumumab patent listed is US 9,115,785 B2 granted in 2015.
No patent listings are included in the supplied label excerpts.
The patent expiry for US 9,115,785 B2 is 2033.
No patent expiry information is included in the supplied label excerpts.
As patents and exclusivity rights expire, generic or biosimilar versions of the drug become available for the market.
No statements regarding generic/biosimilar availability or patent expiration consequences are included in the supplied label excerpts.
Contradictions
Important Omissions
Any dosing/administration information for ofatumumab/KESIMPTA (e.g., administration route, initiation regimen, or maintenance schedule) was not provided, and the evaluation request includes dosage and administration alignment categories.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only on-label, label-supported claim provided concerns the MS indication. However, multiple additional claims (other indications, mechanism, and patent/generic statements) are unsupported by the supplied labeling text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Most claims are unsupported because the supplied prescribing information excerpts address KESIMPTA for relapsing forms of MS and provide no support for the other ofatumumab (Arzerra) mechanism, other indications, or patent/generic-related assertions.
Suggested Improvement
Limit claims to what is explicitly supported in the provided label excerpts (e.g., the relapsing MS indication) and remove or clearly qualify any mechanism, other indications (CLL, rheumatoid arthritis), patent, and biosimilar availability assertions that are not present in the supplied labeling.